Belimumab is approved by the FDA: What more do we need to know to optimize decision making?

Current Rheumatology Reports

Volumn 14, Issue 4, 2012, Pages 318-323

  Horowitz, Diane Lewis ^a   Furie, Richard ^a  

^a DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

Approval; Belimumab; Biologic treatment; Discontinue; FDA; Lupus; Response; SLE; Systemic lupus erythematosus

Indexed keywords

BELIMUMAB; PLACEBO;

ARTICLE; CLINICAL DECISION MAKING; CLINICAL FEATURE; CLINICAL PRACTICE; DISEASE ACTIVITY; DISEASE SEVERITY; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG USE; FOOD AND DRUG ADMINISTRATION; HUMAN; LOW DRUG DOSE; PATIENT CARE; PRACTICE GUIDELINE; PROCESS OPTIMIZATION; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; TREATMENT INDICATION;

ANTIBODIES, MONOCLONAL; AUTOANTIBODIES; DECISION MAKING; DRUG APPROVAL; HUMANS; IMMUNOLOGIC FACTORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PATIENT SELECTION; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84864863234     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-012-0256-4     Document Type: Article

References (15)

1. Furie R, Stohl W, Ginzler EM, Becker M, Mishra N, et al. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther. 2008;10(5):R109.
2. Wallace DJ, Stohl W, Furie RA, Lisse JR McKay JD, et al. A phase II, randomized, double-blind, placebo controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009; 61(9): 1168-1178.
3. Navarra SV, Guzman RM, Gallacher AE, Hall S, Levy RA et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomized, placebo-controlled, phase 3 trial. Lancet 2011; 377(9767): 721-731.
4. Furie RA, Petri M, Zamani O, Cervera R, Wallace DJ. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011; 63(12): 3918-3930.
5. FDA. Guidance for Industry Systemic Lupus Erythematosus-Developing Medical Products for Treatment. June 2010. Found at http://wwjhw.fda.gov/ downloads/Drugs/GuidanceCompliance RegulatoryInformation/Guidances/ucm072063.pdf (accessed 2/8/2012).
6. Furie RA, Petri MA, Wallace DJ, Ginzler EM, Merrill JT, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 2009;61(9):1143-51.
7. Manzi S, Sanchez-Guerreo, Merrill JT, Furie RA, Gladman D, et al. Belimumab, a BlyS-specific inhibitor, reduced disease activity across multiple organ domains: combined efficacy results from the phase 3 BLISS-52 and-76 studies. Arthritis Rheum. 2010;62 (10):607-8.
8. Van Vollenhoven RF, Petri M, Cervera R, Kleoudis C, Zhong ZJ, et al. Factors associated with belimumab treatment benefit: Results from phase 3 studies in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63(10):S554-5.
9. FDA. Briefing Document for the Arthritis Advisory Committee Meeting November 16, 2010. Found at http://www.fda.gov/downloads/advisorycommittees/ committeesmeetingmaterials/drugs/arthritisdrugsadvisorycommittee/ucm233579.pdf (accessed 2/8/2012)
10. Dooley MA, Houssiau F, Aranow C, D'Cruz DP, Askanase AD, et al. Effect of belimumab treatment on renal outcomes: results from phase 3 belimumab clinical trials in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63(10): S963-4.
11. Strand V, Levy RA, Cervera R, Petri MA, Rudge H, et al. Belimumab, a BLyS-specific inhibitor, improved fatigue and SF-36 physical and mental component summary scores in patients with SLE: BLISS-76 and-52 studies. Arthritis Rheum. 2010;62(10):S773.
12. Van Vollenhoven RF, Gallacher A, Navarra S, Ginzler EM, Dooley MA, et al. Belimumab, BLyS-specific inhibitor, reduced cortico-steroid use in patients with active SLE: results from the phase 3 BLISS-52 and-76 studies. Arthritis Rheum. 2010;62(10):189.
13. Cervera R, Furie RA, Levy RA, Roth D, Hough DR, Zhong. Relationship of belimumab treatment response with corticosteroid use and severe flares in patients with SLE: BLISS-52 and BLISS-76. Ann Rheum Dis. 2011;70(Suppl3):321.
14. Petri M, Furie R, Merrill J, Wallace D, Stohl W, et al. Six year experience with belimumab in patients with SLE. Ann Rheum Dis. 2011;70(Suppl3):314.
15. Merrill JT, Furie RA, Wallace DJ, Stohl W, et al. Sustained disease improvement and safety profile over the 1500 patient-year experience (6 years) with belimumab in patients with systemic lupus erythema-tosus. Arthritis Rheum. 2011;63(10):S222.